Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03978611
Title A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Bristol-Myers Squibb



Ipilimumab + Relatlimab

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST